Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Mettens

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Tuberculosis (Edinburgh, Scotland)|December 11, 2012
The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II studyFrançois Spertini, Régine Audran, Floriana Lurati, et al.
Journal of Clinical Immunology|October 22, 2013
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adultsJaime Montoya, Juan Antonio Solon, Soledad Rosanna C Cunanan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Infection and Immunity|February 20, 2007
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine aloneV Ann Stewart, Shannon M McGrath, Patrice M Dubois, et al.
American Journal of Respiratory and Critical Care Medicine|January 12, 2013
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adultsCheryl L Day, Michele Tameris, Nazma Mansoor, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Tuberculosis (Edinburgh, Scotland)|December 11, 2012
The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II studyFrançois Spertini, Régine Audran, Floriana Lurati, et al.
Journal of Clinical Immunology|October 22, 2013
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adultsJaime Montoya, Juan Antonio Solon, Soledad Rosanna C Cunanan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Infection and Immunity|February 20, 2007
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine aloneV Ann Stewart, Shannon M McGrath, Patrice M Dubois, et al.
American Journal of Respiratory and Critical Care Medicine|January 12, 2013
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adultsCheryl L Day, Michele Tameris, Nazma Mansoor, et al.
Pageof 2